Skip to main content
All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q3 report for NOVARTIS on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for NOVARTIS · Innovative medicines company.

All filings by DLA PIPER LLP (US) · Everything NOVARTIS has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Copyright/Patent/Trademark

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Taxation/Internal Revenue Code

Tax reform and tax policy.

Trade (domestic/foreign)

Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).

Health Issues

Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.

Medicare/Medicaid

Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.

 Bills named in this filing 4
  • S. 5316
    BINSA Act
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • S. 832
    EPIC Act of 2025
  • H.R. 1672
    Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem